BioTech Nation ... with Dr. Moira Gunn Moira Gunn
-
- Science
Welcome to BIOTECH NATION !!! With understandable interviews requiring no background in science, BTN attracts a wide global audience. From everyday people looking for hope in treatments in development, to bioentrepreneurs interested in the experience of their fellow travelers, to venture capitalists looking for possibilities in cutting-edge breakthroughs, to scientists simply interested in the work of others, BioTech Nation is the voice of human endeavor, driving science to new realities for everyone. These interviews are drawn directly from the public radio program, "Tech Nation", which also can be heard in numerous global radio and podcasting venues.
-
How Can a Treatment Become a Vaccine??? Dr. Peter DeMuth, Chief Scientific Officer at Elicio Therapeutics
Dr. Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, discusses the revolutionary approach of detecting cancer at its earliest stages through circulating tumor DNA (ctDNA) tests. Highlighting their innovative treatment method, which aims to train the body's immune cells to recognize and destroy cancer cells, the episode explores the potential transition from treatment to vaccine, offering hope for more effective and durable solutions.
-
Cancer Vaccines??? Dr. Chris Pirie, Co-Founder & COO of HDT Bio
In this week's episode, Dr. Moira Gunn interviews Dr. Chris Pirie from HDT Bio about their novel approach to cancer prevention through vaccines. They discuss leveraging mRNA technology to target specific tumor mutations and prime the immune system to recognize and eliminate cancer cells. Dr. Pirie highlights ongoing efforts to develop vaccines for prostate, pancreatic, and breast cancers, emphasizing the importance of monitoring immune responses in clinical trials. They also explore the potential for broad-spectrum cancer vaccines and the need to shift towards preventive measures in cancer treatment.
-
Redefining Acute Myeloid Leukemia (AML) Treatment!!! Dr. Robert Ang, President & CEO of Vor Biopharma
This week I speak with Dr. Robert Ang from Vor Biopharma about their innovative approach to treating acute myeloid leukemia (AML). AML is a type of blood cancer that affects the bone marrow, leading to the overgrowth of cancerous cells. Dr. Ang explains that traditional treatments, such as chemotherapy and stem cell transplants, have limitations and risks. Dr. Ang emphasizes the potential of their treatment to revolutionize AML therapy and improve patient outcomes.
-
Fighting Inflammation, and Alzheimer's??? Dr. David Bearss, President & CEO Halia Therapeutics
In this week's episode of BioTech Nation, Dr. David Bearss, President and CEO of Halia Therapeutics, discusses inflammation and its reduction over a lifetime and in response to various incidents. He unveils the inflammasome, a recently discovered protein complex critical in regulating inflammatory responses and its potential in treating chronic diseases like myelodysplastic syndrome and Alzheimer's. Dr. Bearss shares insights into Halia's groundbreaking approach and his relentless pursuit of medical breakthroughs.
-
Food as Medicine, A Personalized Prescription... Dr. Daniel Kraft, Tech Nation Health Chief Correspondent
Tech Nation Health, Chief Correspondent Dr. Daniel Kraft discusses the concept of "food as medicine." Dr. Kraft emphasizes the evolving understanding of nutrition and its profound impact on health, advocating for a shift towards personalized nutrition using cutting-edge technologies. From continuous glucose monitors to AI-powered apps and sensor toilets, we explore how these innovations enable individuals to measure and optimize their dietary choices.
-
Repairing Minds, Naturally??? Mark Litton, President & CEO, Athira Pharma
Alzheimer’s, Parkinson’s dementia, and other neurodegenerative diseases continue to be challenging, but now new science has led to a better understanding of the natural repair mechanisms in the brain. This, in turn, has generated new options for innovative treatments, and one such approach has entered late-stage human clinical trials. Dr. Mark Litton is the President and CEO of Athira Pharma.